Cytokine Release Syndrome Management Market Report 2026

The cytokine release syndrome management market size has grown strongly in recent years. It will grow from $23.76 billion in 2025 to $25.31 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to growth of car-t therapies, limited crs treatment options, reliance on corticosteroids, hospital-based management, high mortality risk.

The cytokine release syndrome management market size is expected to see strong growth in the next few years. It will grow to $32.35 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to expansion of cell therapies, advancements in immunomodulators, improved early detection, standardized treatment guidelines, increasing oncology adoption. Major trends in the forecast period include rising use of il-6 inhibitors, expansion of crs management in car-t therapy, increased focus on early intervention protocols, growth of intensive care monitoring, development of targeted immunomodulators.

The increasing adoption of targeted therapies is anticipated to drive the growth of the cytokine release syndrome management market in the coming years. Targeted therapies are treatments specifically developed to inhibit the growth and spread of cancer by acting on molecular targets involved in tumor progression. Their rising use is mainly attributed to their ability to accurately target cancer cells while limiting harm to healthy tissues, thereby enhancing treatment effectiveness and lowering side effects compared to conventional therapies. Cytokine release syndrome management plays a vital role in supporting targeted therapies by controlling severe inflammatory responses, which improves the safety and performance of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For instance, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based organization focused on gene and cell therapy, the fourth quarter of 2023 saw a 10% increase in the number of gene therapies in Phase III clinical trials, representing the first quarterly increase since the third quarter of 2022. As a result, the growing use of targeted therapies is contributing to the expansion of the cytokine release syndrome management market.

Major companies operating in the cytokine release syndrome management market are prioritizing clinical trials to develop advanced therapies, including host-directed small molecule drugs, that aim to regulate immune responses and lessen the intensity of cytokine storms without weakening the body’s ability to combat infections or cancer. A host-directed small molecule drug is a low molecular weight compound designed to act on the host’s immune signaling pathways to reduce excessive cytokine production, thereby supporting the management of cytokine release syndrome (CRS) by preventing immune system overactivation. For example, in April 2025, CytoAgents Inc., a US-based biotechnology company, reported the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule therapy developed to prevent and treat CRS in patients undergoing CAR T-cell therapy. The investigational drug showed a favorable safety profile, with no dose-limiting toxicities or negative impact on CAR T-cell effectiveness. The trial, which follows a rolling six dose-escalation design, is being conducted to evaluate the safety, tolerability, and early efficacy of CTO1681, as well as to determine the recommended Phase 2 dose.

In March 2024, Merck & Co., Inc., a US-based biopharmaceutical company, completed the acquisition of Harpoon Therapeutics for $680 million. Through this acquisition, Merck seeks to enhance its oncology pipeline by incorporating Harpoon’s T-cell engager technology and its lead candidate, MK-6070, which is currently in a Phase 1/2 clinical trial (NCT04471727) for advanced cancers, thereby strengthening its presence in immuno-oncology and broadening its next-generation cancer treatment portfolio. Harpoon Therapeutics Inc. is a US-based clinical-stage biopharmaceutical company focused on developing T-cell engagers for cancer therapy, with its TriTAC-XR platform designed to reduce cytokine release syndrome and improve treatment efficacy.

Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.

North America was the largest region in the cytokine release syndrome management market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cytokine release syndrome management market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cytokine release syndrome management market by increasing costs of imported biologics, monoclonal antibodies, and critical care drugs. Hospitals in North America and Europe are most affected due to reliance on imported immunotherapies, while Asia-Pacific faces higher access costs. These tariffs are increasing treatment expenses. However, they are also encouraging local biologics manufacturing and supply chain resilience.

The cytokine release syndrome management market research report is one of a series of new reports that provides cytokine release syndrome management market statistics, including cytokine release syndrome management industry global market size, regional shares, competitors with a cytokine release syndrome management market share, detailed cytokine release syndrome management market segments, market trends and opportunities, and any further data you may need to thrive in the cytokine release syndrome management industry. This cytokine release syndrome management market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cytokine release syndrome (CRS) management refers to medical approaches used to control an excessive immune response triggered by the overproduction of cytokines, commonly associated with treatments such as CAR-T cell therapy or certain infections. It involves the use of drugs such as corticosteroids and cytokine inhibitors, along with supportive care and, in some cases, intensive monitoring to avoid serious complications. Effective management plays an important role in lowering the risk of severe organ damage and improving patient outcomes.

The primary treatment options for cytokine release syndrome management include monoclonal antibodies, corticosteroids, intravenous immunoglobulin (IVIG), targeted therapies, supportive care, and other treatment approaches. Monoclonal antibodies are laboratory-developed agents designed to target specific cytokines or their receptors to modulate immune responses and control CRS. These therapies are used across multiple indications, such as chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, hematopoietic stem cell transplantation (HSCT), autoimmune disorders, infections, and others, and can be administered through intravenous (IV), subcutaneous (SC), oral, intramuscular (IM), intrathecal, and other routes. These treatment options are used by various end users, including hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, research institutions, and others.

The cytokine release syndrome management market consists of revenues earned by entities by providing services such as diagnostic testing, immunosuppressive therapy, supportive care, clinical trial services, and post-treatment monitoring to manage and treat patients affected by CRS. The market value includes the value of related goods sold by the service provider or included within the service offering. The cytokine release syndrome management market also includes sales of tocilizumab (actemra), siltuximab (sylvant), dexamethasone, ruxolitinib (jakafi), and ivig (intravenous immunoglobulin). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.